News | Magnetic Resonance Imaging (MRI) | July 24, 2025

Following the recent FDA clearance of the new Swoop System, two leading hospitals in the U.S. have purchased the first commercial units, marking the launch of next-generation portable MR brain imaging.

Hyperfine Announces the First Commercial Sales of the Next-Gen Portable MRI  System

July 17, 2025 – Hyperfine, Inc.recently announced the first commercial sales of the next-generation Swoop system.The Swoop system is the first FDA-cleared AI-powered portable MRI system for the brain. The Swoop system is powered by proprietary Optive AI software.

Two pioneering hospitals in the northeast U.S. plan to utilize the technology in their intensive care units and emergency department settings.

The initial sales of the next-generation Swoop system—purchased by two top-tier hospitals in the northeastern United States—demonstrate a strong market response following FDA clearance and mark a critical step toward the widespread clinical adoption of portable brain imaging with diagnostic-level clarity.

“This marks the start of a new phase for Hyperfine — one where our vision to transform MRI access is driven by a new system that is commercially ready, is clinically valuable, has outstanding image quality and functionality, and is garnering strong customer interest,” commented Maria Sainz, president and CEO of Hyperfine. “Attaining the milestone of first commercial sales and deliveries of the new Swoop system just weeks after FDA clearance is the result of seamless execution across the organization — from industry-leading product development to accelerated clearance to rapid manufacturing ramp to initial sales. We are excited about the momentum with the new Swoop system and the growth we anticipate in the second half of 2025 and beyond.”

The new Swoop system features innovations specifically engineered to deliver the highest signal-to-noise ratio, which, when paired with the Optive AI software, achieve exceptional image quality, including improved resolution, uniformity, and faster acquisition times. This new level of image quality has the potential to dramatically drive the adoption of the Swoop system across sites of care and multiple clinical applications. The new Swoop® system also delivers a user and patient-centric design to accommodate a broad patient population—especially beneficial for pediatric, elderly, or anxious patients—making MRI more accessible for all.

For more information about the Swoop Portable MR Imaging system, please visit HyperfineMRI.com.


Related Content

News | Radiology Imaging

Feb. 12, 2026 — Siemens Healthineers and Mayo Clinic are expanding their strategic collaboration to enhance patient care ...

Time February 13, 2026
arrow
Feature | Cardiac Imaging | Kyle Hardner

Advances in coronary CT angiography (CCTA) have reached the point where image quality and AI capabilities are creating ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 6, 2026 — A state-of-the-art intraoperative MRI (iMRI) has arrived at the University of Chicago Medicine, one of ...

Time February 06, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Feb. 5, 2026 — Eyas Medical Imaging, Inc. has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its ...

Time February 06, 2026
arrow
News | Ultrasound Women's Health

Feb. 5, 2026 — BrightHeart, a global provider of AI-driven prenatal ultrasound, has announced the availability of its B ...

Time February 05, 2026
arrow
News | Lung Imaging

Feb. 3, 2026 — RevealDx, a leader in the characterization of lung nodules, recently announced FDA clearance of RevealAI ...

Time February 04, 2026
arrow
News | FDA

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ...

Time February 03, 2026
arrow
News | Interventional Radiology

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
Subscribe Now